Due to the important roles of mot‐2 in cancer migration and invasion (Chen et al., 2014; Na et al., 2016; Ryu et al., 2014; Yi et al., 2008), establishing VTD as a potent mot‐2 destabilizer molecule will set up a unique platform for new preclinical drug development in different types of cancer, including colorectal cancer. This evidence concerns the gene HSPA9 and cancer.